Clinical and microbiological observations on CDC group DF-3, a gram-negative coccobacillus.
Sequential stool cultures submitted for routine culture were screened for the presence of CDC group DF-3. Of 690 specimens, 11 (1.6%) yielded moderate to heavy growth of DF-3. Information on the 11 patients from whom these specimens were obtained showed that 4 had a history of prolonged diarrheal disease that resolved after specific therapy to eradicate DF-3, while for the other 7 patients no clear role could be established. Microbiological characterization of the stool isolates and 10 CDC strains of DF-3 suggested the presence of two subtypes within the group. Antibiotic susceptibility studies showed DF-3 to be relatively resistant to a wide variety of antibiotics.
Gill
V J
VJ
Department of Clinical Pathology, Warren Grant Magnuson Clinical Center, National Cancer Institute, Bethesda, Maryland 20892.
Travis
L B
LB
Williams
D Y
DY
D000293:Adolescent; D000328:Adult; D000368:Aged; D001426:Bacterial Proteins; D001427:Bacterial Toxins / Q000032:analysis; D017000:Campylobacter coli; D016123:Campylobacter jejuni; D003967:Diarrhea / Q000188:drug therapy / Q000382:microbiology; D004318:Doxycycline / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005243:Feces / Q000382:microbiology*; D005260:Female; D006092:Gram-Negative Facultatively Anaerobic Rods / Q000145:classification*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013752:Tetracycline / Q000627:therapeutic use
D001426:Bacterial Proteins; D001427:Bacterial Toxins; C031815:toxB protein, Clostridium difficile; D013752:Tetracycline; D004318:Doxycycline